Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

Ahmed Sawas,Helen Ma,John Kuruvilla,Jennifer K. Lue,Changchun Deng,Enrica Marchi,Francesca Montanari,Bin Cheng,Kerry J. Savage,Diego Villa,Michael Crump,Joseph M. Connors,Owen A. O’Connor

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

2020

Ahmed Sawas
Helen Ma
John Kuruvilla
Jennifer K. Lue
Changchun Deng
Enrica Marchi
Francesca Montanari
Bin Cheng
Kerry J. Savage
Diego Villa
Michael Crump
Joseph M. Connors
Owen A. O’Connor

Classical Hodgkin lymphoma (cHL) is a malignancy that arises from clonal germinal center B-cells [1]. Despite favorable outcomes in the front-line setting for most patients, 20–30% of patients deve...

Keywords:

phase i ii
Bendamustine
Brentuximab vedotin
Internal medicine
Progression-free survival
Refractory Hodgkin Lymphoma
Medicine
Oncology
Immunology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations